重组抗小鼠CD8(Lyt 2.1)单抗(116-13.1) | Syd Labs PA007552.m2a
体内实验级重组抗小鼠CD8 (Lyt 2.1) 单抗（克隆号：116-13.1，货号：PA007552.m2a），小鼠IgG2a Kappa 是用哺乳动物细胞生产的重组抗体，纯度>95%，适用于体外和体内研究，比如体内CD8+T细胞耗竭（清除）。Syd Labs PA007552.m2a抗小鼠CD8 (Lyt 2.1) 抗体不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007552.m2a |
|---|---|
| 产品名称 | 重组抗小鼠CD8(Lyt 2.1)单抗(116-13.1) | Syd Labs PA007552.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-mouse CD8 (Lyt 2.1) Monoclonal Antibody (Clone: 116-13.1), Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | CD8；分化簇8；CD8a；CD8b；CD8A；CD8B；CD8B1 |
| 概述 | Syd Labs 重组抗小鼠CD8 (Lyt 2.1) 单克隆抗体(克隆：116-13.1) 是用哺乳动物细胞生产的重组抗体，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 116-13.1 |
| 同种型 | 小鼠 IgG2a, kappa |
| 特异性 | 体内实验级重组小鼠单克隆抗体 (克隆：116-13.1) 特异性与小鼠 CD8 (Lyt 2.1) 结合 |
| 抗体形式 | 0.2 μM过滤溶液，pH 7.4，不含稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠CD8 (Lyt 2.1) 单克隆抗体（克隆号116-13.1)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存1个月。 如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007552.m2a Syd Labs：体内实验级重组抗小鼠CD8 (Lyt 2.1) 单克隆抗体是用哺乳动物细胞生产的，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受小鼠CD8 (Lyt 2.1)蛋白影响的生物途径的测定 |
文献
PA007552.m2a: Syd Labs体内实验级重组抗小鼠CD8 (Lyt 2.1) 单克隆抗体（克隆号116-13.1），小鼠IgG2a Kappa（In Vivo Grade Recombinant Anti-mouse CD8 (Lyt 2.1) Monoclonal Antibody (Clone: 116-13.1), Mouse IgG2a Kappa)）
体内实验级重组抗小鼠CD8 (Lyt 2.1) 单克隆抗体（克隆号116-13.1，小鼠IgG2a Kappa）是针对小鼠CD8α链（Lyt 2.1等位基因/同工型）的序列明确（sequence-defined）重组单克隆抗体。小鼠CD8蛋白（Lyt 2）是表达于细胞毒性T细胞（CTLs）及部分树突状细胞表面的关键共受体，在MHC I类分子约束的免疫应答与细胞毒性发挥中占据核心地位。该重组抗小鼠CD8单克隆抗体（克隆号116-13.1）采用哺乳动物细胞重组表达系统生产，克服了传统杂交瘤来源抗体易出现基因漂移、轻链污染及批次不稳定的缺陷，能够特异性结合Lyt 2.1表达型小鼠（如A/J、C3H、SJL、AKR等品系）的CD8+ T细胞，为靶向特定小鼠品系中的CD8+ T细胞功能研究与免疫调控提供了高保真的科研试剂。
在体内实验与肿瘤免疫学研究中，体内实验级重组抗小鼠CD8 (Lyt 2.1) 单克隆抗体（克隆号116-13.1）广泛应用于小鼠体内CD8+ T细胞清除（In Vivo CD8+ T Cell Depletion）、异基因移植排斥反应机制探索及感染免疫模型构建。凭借重组小鼠IgG2a Kappa格式强大的Fc段效应功能，该抗体能够强效激活宿主的ADCC（抗体依赖性细胞毒性）和CDC（补体依赖性细胞毒性）机制，实现目标CD8+ T细胞的高效介导与清除。为满足严苛的动物体内注射标准，该重组抗小鼠CD8 (Lyt 2.1) 抗体（克隆号116-13.1）经过多步精细纯化，具备超低内毒素（<1 EU/mg）和无防腐剂（PBS配方）特性，能有效避免全身性非特异性免疫激活，确保肿瘤免疫治疗与细胞免疫学实验生成干净、高可重复性的科研数据。
抗小鼠 CD8 (Lyt 2.1) 单克隆抗体（克隆号：116-13.1）参考文献：
1. Binary outcomes of enhancer activity underlie stable random monoallelic expression.
Nagano, T., et al. eLife. 2022 May 26;11:e74204. PMID: 35617021
“Anti-CD8.1 (116-13.1) unconjugated, anti-CD8.2 (2.43) unconjugated. Klra1 Hss1-/- mice were generated by microinjection, while Klrc1 5’E+/-, Klrk1 5’E+/- and Klra7 Hss1-/- mice were generated by CRISPR-EZ electroporation. Founder mice (F0) harboring deletion alleles were backcrossed to C57BL/6J (B6) mice to generate heterozygous F1 mice, and were then intercrossed to generate WT, heterozygous and homozygous littermates for experiments. F1 hybrid mice between B6-Klrc1 5’E+/+ and BALB/c mice were generated (Klrc1 B6-5’E+/BALB/c+ heterozygotes) along with WT F1 littermates.”
2. Salp15, an Ixodes scapularis salivary protein, inhibits CD4(+) T cell activation.
Garg, R., et al. J Immunol. 2002 Jul 1;169(1):418-24. PMID: 12121666
“Mice were depleted of CD8+ T cells by i.p. injection of 500 µg anti-CD8 mAb (clone 116-13.1) on days -1, 1, and 7 relative to immunization. Splenocytes from immunized mice were harvested 7 days after the last immunization. CD4+ T cells were purified using magnetic bead separation. Proliferation was measured by [3H]thymidine incorporation after 72 hours. Cytokine levels in culture supernatants were determined by ELISA.”
3. Amplification of tumor immunity by gene transfer of the co-stimulatory molecule B7.
Guha-Thakurta, N., et al. Eur J Immunol. 1998 Mar;28(3):1116-25. PMID: 9541607
“Purified mAb 116-13.1 (anti-CD8) was administered i.p. at 200 µg per mouse to deplete CD8+ T cells. Tumor cells were injected subcutaneously into syngeneic mice. Tumor growth was monitored twice weekly with calipers. Survival of mice was recorded daily. Histological analysis of tumors was performed on day 14 post-inoculation.”
Swat, W., et al. J Exp Med. 1992 Apr 1;175(4):1013-22. PMID: 1532412
“Anti-CD8 monoclonal antibody (clone 116-13.1) was injected intraperitoneally into pregnant females at 100 µg per dose. Thymocytes were analyzed by flow cytometry 48 hours post-injection. Transgenic mice were crossed to generate double transgenics. Peripheral T cell numbers were enumerated in spleen and lymph nodes. Positive and negative selection was assessed in thymic sections.”
5. Human papillomavirus type 16 nucleoprotein E7 is a tumor-rejection antigen.
Chen, L., et al. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):110-4. PMID: 1846033
“Depletion of CD8+ T cells was achieved by i.p. administration of mAb 116-13.1 (200 µg/mouse) three days before tumor challenge. Mice were immunized with E7-expressing vaccinia virus. Tumor regression was observed in 80% of immunized mice. Control mice received parental vaccinia. CTL activity was measured using 51Cr release assay.”